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The development of depressive disorders had long been attributed to monoamine
variations, and pharmacological treatment strategies likewise focused on methods of
altering monoamine availability. However, the limited success achieved by treatments that
altered these processes spurred the search for alternative mechanisms and treatments.
Here we provide a brief overview concerning a possible role for pro-inflammatory
cytokines and growth factors in major depression, as well as the possibility of targeting
these factors in treating this disorder. The data suggest that focusing on one or another
cytokine or growth factor might be counterproductive, especially as these factors may
act sequentially or in parallel in affecting depressive disorders. It is also suggested that
cytokines and growth factors might be useful biomarkers for individualized treatments of
depressive illnesses.
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Major depression is not only the most common neuropsychiatric
disorder, but it is also highly comorbid with other pathologi-
cal conditions, including anxiety disorders, schizophrenia, heart
diseases, auto-immune illnesses, metabolic syndrome, diabetes,
neurodegenerative disorders, and post-stroke neuropsychiatric
complications (Anisman et al., 2008). Unfortunately, the available
treatment strategies have not been overwhelmingly successful in
attenuating depressive symptoms in all patients, and the specific
processes involved in the pathogenesis of depressive illnesses have
yet to be fully identified. In this regard, in the past decade there
has been increasing attention devoted to the possibility that both
inflammatory and growth factors might play a provocative role in
depression. In the present report we will explore the possibility
that pro-inflammatory cytokines, which had traditionally been
thought of as signaling molecules of the inflammatory immune
system, but which are also endogenously produced in the brain,
might come to interact with growth factors, thereby influenc-
ing neuronal and synaptic growth and plasticity, and ultimately
promoting depressive illnesses.
IMPLICATIONS OF THE INFLAMMATORY IMMUNE SYSTEM
IN DEPRESSIVE ILLNESSES
The search for new antidepressant strategies has recently
generated a growing interest especially as a significant per-
centage of depressed patients do not respond positively to
medication. In fact, traditional treatments aimed at increas-
ing monoamine concentrations, including tricyclic antide-
pressants (TCAs), monoamine oxidase inhibitors (MAOIs),
selective serotonin reuptake inhibitors (SSRIs), or serotonin-
norepinephrine reuptake inhibitors (SNRIs), attenuate depressive
symptoms in only 50–60% of individuals, although combina-
tion drug therapies can yield appreciably improved success rates
(Blier et al., 2010). When drug treatments are effective in reduc-
ing depression, remission is often incomplete and the relapse rates
may exceed 50% over a 5-year period (Moncrieff and Kirsch,
2005). As antidepressant effects are usually observed only after
2–3 weeks of treatment, patients may also be at risk for harm dur-
ing this period, especially as multiple attempts might be needed
before an effective treatment is found. As well, several undesir-
able side effects frequently accompanied antidepressant therapy,
including agitation, sexual dysfunction, and weight gain, which
might precipitate treatment discontinuation or patients tak-
ing “drug holidays.” Thus, identification of additional processes
involved in depression has been the focus of intensive efforts in
order to develop alternative treatments or multi-targeted thera-
pies aimed at attenuating symptoms sooner and more efficiently.
INCREASED ACTIVITY OF PRO-INFLAMMATORY CYTOKINES IN
INDIVIDUALS WITH MAJOR DEPRESSION AND IN ANIMAL MODELS
OF THE DISORDER
One research avenue that has received considerable attention
has concerned the possibility that increased activity of pro-
inflammatory cytokines might contribute to the pathogenesis of
depressive illnesses (Maes, 1995). Pro-inflammatory cytokines are
signaling molecules of the inflammatory immune system that ini-
tiate and coordinate the cascade of immune events necessary to
deal with infection, toxins, injury, and/or trauma. Table 1 shows
a subset of the many cytokines that have been identified in cir-
culation as well as in various brain regions, including those that
have anti-inflammatory properties. Importantly, these cytokines
have been hypothesized as being involved in the provocation of
mood disorders, such as depressive illnesses.
Consistent with a role for cytokines in depression, meta-
analyses have established that circulating concentrations of the
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Table 1 | Subset of pro- and anti-inflammatory cytokines that had been implicated in depressive illnesses: potential roles in behavioral
processes and/or neuropsychiatric disorders.
Cytokine
name
Immune cells
(main source)
Major actions Major outcomes Behavioral processes/
neuropsychiatric disorders
PRO-INFLAMMATORY
Interleukins IL-1β Macrophages,
monocytes,
dendritic cells
Stimulates immune cells and
pro-inflammatory cytokines,
activates microglia, regulates
growth factor activity
Acute phase response, fever,
wound healing, pain
hypersensitivity, angiogenesis
Sickness behaviors, stress
response, cognitive
processes, depression,
anxiety, schizophrenia,
Alzheimer’s disease
IL-2 Th1 cells Growth and differentiation of
T cells
Immune homeostasis Depression, schizophrenia
IL-6 Macrophages,
Th2 cells
Synthesis of acute phase
proteins, growth and
differentiation of T and B
cells, secretion of antibodies.
Regulates pro-inflammatory
factors (anti-inflammatory
actions)
Acute phase response, fever,
fighting infection
Stress response,
depression, post-traumatic
stress disorder (PTSD),
Alzheimer’s disease,
schizophrenia
IL-18 Macrophages,
dendritic cells
Stimulates maturation of T
and NK cells, stimulates
production of IFN-γ,
negatively regulates IL-4
Regulates homeostasis Post-stroke depression,
hyperphagia, metabolic
syndrome
Interferons IFN-α B, T, and NK
cells
Activates macrophages and
NK cells
Flu-like symptoms (e.g., fever) Depression, cognitive
processes (delirium)
IFN-γ Th1 and NK
cells
Activates macrophages and
NK cells, activates microglia
Flu-like symptoms (e.g.,
fever), anti-tumoral
Emotionality disturbances
Tumor necrosis
factor
TNF-α Macrophages,
Th1 cells, NK
cells,
mastocytes
Stimulates immune cells,
activates microglia, systemic
inflammation, tissue
destruction
Acute phase response, fever,
sepsis
Sickness behaviors,
depression, autoimmune
diseases
Other factors MIF Macrophages,
fibroblasts
Blocks anti-inflammatory
effects of glucocorticoids
Enhances inflammatory
response, neurogenesis
Depression
ANTI-INFLAMMATORY
Interleukins IL-4 Th2 cells,
mastocytes,
basophils
Stimulates differentiation of
Th2 and B cells, decreases
production of Th1 cells
Limits pathological
inflammation
Allergies, ischemic stroke,
auto-immune diseases,
suicide
IL-10 Monocytes,
Th1 and Th2
cells
Decreases pro-inflammatory
cytokines from macrophages
and Th1 cells, stimulates Th2
and B cells, inhibits NK cells
Represses inflammatory
immune response
Depression, schizophrenia
pro-inflammatory cytokines interleukin (IL)-6 and tumor necro-
sis factor (TNF)-α were elevated in non-medicated depressed
patients, whereas variations of IL-1β were less consistently
demonstrated (Dowlati et al., 2010; Liu et al., 2012a), possibly
because of the difficulty in detecting the very low levels of this
interleukin in human circulation. In contrast, lower serum levels
of the anti-inflammatory cytokine IL-10 and higher IL-6/IL-10
ratios were found in drug-free depressed individuals, and low IL-
10 levels were negatively correlated to depressive scores (Dhabhar
et al., 2009). In keeping with the view that stressful events might
influence cytokine levels and thus promote depression, a meta-
analysis revealed that psychosocial stressors increased plasma
concentrations of pro-inflammatory cytokines, especially that of
IL-6 (Steptoe et al., 2007), and this outcome was greater among
individuals with a history of childhood maltreatment (Carpenter
et al., 2010), a condition that also favors the development of
depression. Plasma IL-1β concentrations were also elevated after
psychosocial stressors in humans, but this change was fairly
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transient (Steptoe et al., 2007; Yamakawa et al., 2009), again
supporting the view that this cytokine in the blood might play
a less prominent role in depression, although these data may
not speak to the central involvement of IL-1β in mediating this
disorder.
Parenthetically, even though the available data point to the
fundamental involvement of IL-6 in relation to depressive ill-
nesses, this should not be taken to mean that other cytokine
variations, especially those that occur in the brain, are not rel-
evant to the evolution of depression. In fact, a small portion
of the pro-inflammatory cytokines released into circulation can
gain access to the brain at the blood-brain barrier and spread
through volume diffusion at circumventricular sites (Vitkovic
et al., 2000) or may reach the brain through saturable transport
systems (Banks, 2006). In addition, brain microglia may produce
pro-inflammatory cytokines in response to inflammatory stim-
uli or stressors (Quan et al., 1998; Dantzer et al., 2008; Sukoff
Rizzo et al., 2012). The elevations of pro-inflammatory cytokines
are not restricted to regions that are associated with hormonal
changes (e.g., hypothalamus), but have been documented in the
prefrontal cortex (PFC), hippocampus, amygdala, as well as other
brain regions that are involved in stressor appraisal processes and
depressive illnesses (Anisman et al., 2008).
Among the few studies that have examined brain cytokine
variations associated with depressive illnesses, several pro-
inflammatory cytokines, including IL-1 and a precursor of the
soluble form of TNF-α, TNF trans-membrane, were reported
to be up-regulated in post-mortem PFC of patients with major
depression (Dean et al., 2010; Shelton et al., 2011). Increased IL-
1β, IL-6, and TNF-α in post-mortem PFC were also found in
teenaged individuals that died by suicide, although in this study
not all tissue had come from individuals that had been diagnosed
with major depression (Pandey et al., 2012). A potential role for
brain cytokine elevations in depression has been confirmed in
studies using rodent models of the disorder showing that psy-
chosocial stressors, such as social defeat, increased plasma IL-6,
and IL-1β levels and up-regulated expression of these cytokines
in the PFC and hippocampus (Audet et al., 2010, 2011). Likewise,
fairly strong stressors such as tailshock, footshock, and immo-
bilization increased IL-1β protein and mRNA in serum and in
hypothalamus (O’Connor et al., 2003; Deak et al., 2005) as well as
IL-6 in the frontal cortex (Sukoff Rizzo et al., 2012). Interestingly,
cortical elevations of IL-6 promoted by inescapable footshock
were apparent only in rats that had developed a depressive phe-
notype, suggesting that IL-6 activity (at least in the frontal cortex)
might be particularly aligned with the emergence of depres-
sive features secondary to stressor exposure (Sukoff Rizzo et al.,
2012).
The implications of pro-inflammatory cytokine activation in
relation to depressive illnesses appear to be particularly relevant
to depression that is not readily abated by monoamine-based
antidepressants (Maes et al., 2009). It has, in fact, been suggested
that depressed patients who repeatedly fail to respond to tradi-
tional antidepressants may exhibit a distinctive pro-inflammatory
profile (Krishnadas and Cavanagh, 2012). Consistent with this
perspective, up-regulated IL-1β and TNF-α serummRNA expres-
sion prior to treatment was more pronounced among depressed
patients who did not respond to later SSRIs or TCAs compared to
those who did, and was negatively correlated with clinical out-
comes (Cattaneo et al., 2013). In this particular report, basal
cytokine expression predicted antidepressant efficacy and was
reduced by treatment, but only IL-6 down-regulation was spe-
cific to treatment responders (Cattaneo et al., 2013). Likewise,
the elevated circulating levels of IL-6 prior to medication was
more pronounced in depressed patients that did not respond
to later treatment with TCAs, SSRIs, or SNRIs compared to
those who did respond, and IL-6 elevations were attenuated only
in those patients who responded positively to antidepressants
(Lanquillon et al., 2000; O’Brien et al., 2007; Yoshimura et al.,
2009). The possibility that pre-existing activation of inflamma-
tory processes might promote resistance to antidepressants has
also been confirmed in animal studies. For instance, the posi-
tive actions of fluoxetine were precluded if chronically stressed
rats had been treated with the bacterial endotoxin lipopolysac-
charide (LPS) prior to each stressor treatment (Wang et al.,
2011a). A blunted response to the antidepressant effects of
fluoxetine was also observed in mice engineered to overex-
press IL-6 in the frontal cortex and hippocampus as well as in
mice that had received i.c.v. injections of IL-6, suggesting that
brain elevations of this cytokine might be particularly impor-
tant contributors to antidepressant resistance (Sukoff Rizzo et al.,
2012).
There is some question concerning the clinical significance
of cytokine changes in periphery and in the brain in relation
to depression. In fact, as informative as peripheral cytokine
activity might be, depressive illnesses ultimately are likely more
closely aligned with brain cytokine variations (either endoge-
nously produced or peripherally stimulated) or with effects
secondary to such changes, including variations of neurotrans-
mitters, hormones, or growth factors. What circulating vari-
ations of cytokines in depressed individuals might reflect in
relation to the actual disorder is still uncertain, especially as
clinical improvements elicited by antidepressants are not uni-
formly accompanied by normalization of peripheral cytokine
levels (Eller et al., 2009; Hannestad et al., 2011). Circulating
cytokines might be peripheral biomarkers or trait characteris-
tics of depressive illnesses, as they might also reflect distress
experienced by depressed individuals. It is also possible that
blood cytokine variations may be indicative of those individ-
uals who are at risk for depression or they may be suggestive
of an ongoing biological dysfunction that signifies which indi-
viduals will be more resistant to antidepressants or particularly
prone to relapse following successful therapy. In fact, the spe-
cific contributions of circulating versus brain pro-inflammatory
cytokines in mediating depressive symptoms remain to be
addressed and whether peripheral cytokine changes might pre-
dict brain variations that are translated into depressive conditions
is uncertain.
To this point, we focused primarily on the influence of pro-
inflammatory cytokines in relation to behavioral disturbances.
However, this should not be misconstrued to suggest that periph-
eral factors do not play a role in this regard. For instance,
peripheral epinephrine may stimulate immune activity and
increase cytokine release from immune cells, whereas circulating
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cortisol/corticosterone may have the opposite effects (Anisman
et al., 2008). Once released, as described earlier, these cytokine
changes can directly or indirectly influence central neurochemical
functioning. The use of β-adrenergic receptor antagonists as
adjunctive treatment was shown to accelerate and accentuate
clinical improvements elicited by SSRIs in patients with major
depression (Portella et al., 2011), or in those that experienced
depressive symptoms post-surgery (Battes et al., 2012). Moreover,
in mice, pretreatment with the β-adrenergic antagonist propra-
nolol reversed anxiety-like behaviors and normalized stressor-
induced plasma and brain IL-6 and TNF-α reactivity elicited by
a social stressor (Wohleb et al., 2011; Hanke et al., 2012), thus
suggesting a potential role for epinephrine in cytokine-mediated
mood disturbances elicited by stressors.
In addition to the involvement of epinephrine in immu-
nity and mood disorders, it has been known for some time
that increased cholinergic functioning can affect immune cell
activity and influence depressive-like states (Blalock, 1994; Ofek
et al., 2007; Pavlov et al., 2009; Ofek and Soreq, 2013). In this
regard, cholinesterase inhibitors, that may act to block peripheral
inflammatory processes, attenuated comorbid depressive symp-
toms in patients with Alzheimer’s disease (Spalletta et al., 2012).
However, a meta-analysis revealed that the use of cholinesterase
inhibitors as adjunctive antidepressant therapy had no clear ben-
efit in older adults with depression (McDermott and Gray, 2012),
suggesting that blood cytokine reductions brought about by
acetylcholine manipulations might not be sufficient to atten-
uate depressive symptoms in patients with major depressive
disorder.
DEPRESSIVE EPISODES ASSOCIATED WITH IMMUNOTHERAPY OR
INFLAMMATORY CONDITIONS
Non-medicated patients suffering from chronic inflammatory
illnesses (e.g., multiple sclerosis, chronic hepatitis C, cancer)
or acute inflammatory conditions (e.g., stroke, surgery) com-
monly experienced comorbid depressive symptoms (Musselman
et al., 2001b; Cremeans-Smith et al., 2009). Such findings, of
course, are correlational and hence do not provide a causal link
between inflammatory factors and depressive states. However,
strong evidence causally linking pro-inflammatory cytokines to
depression comes from many reports showing that immunother-
apy with interferon (IFN)-α in the treatment of hepatitis C or
some types of cancer promoted a syndrome similar to that of
major depression, sometimes sufficiently severe to necessitate
treatment discontinuation (Capuron andMiller, 2004). Although
the depressive symptoms generally resolved when IFN-α therapy
ceased, patients were often sensitized so that they were partic-
ularly reactive to further cytokine challenges (e.g., subsequent
treatment) (Loftis and Hauser, 2004).
The development of depression among individuals receiv-
ing IFN-α immunotherapy may be influenced by many of the
same factors that predict major depression under other con-
ditions. In particular, subsyndromal levels of depression prior
to immunotherapy predicted more intense depressive episodes
in response to the IFN-α treatment (Capuron et al., 2004;
Beratis et al., 2005), and depressive symptoms stemming from
the cytokine therapy were more prominent among individuals
with poor social support resources (Capuron et al., 2004).
Furthermore, low levels of tryptophan (Capuron et al., 2003a) as
well as elevated levels of adrenocorticotropic hormone and corti-
sol (Capuron et al., 2003b) in response to IFN-α were predictive
of depressive illnesses. Paralleling the effects ofmanipulations that
reduced tryptophan levels (Young and Leyton, 2002; Neumeister
et al., 2004), depressive symptoms engendered by IFN-α were
more pronounced among women and among those with a his-
tory of depression (Capuron et al., 2003a). Finally, as expected
based on a cytokine perspective of the disorder, depression dur-
ing IFN-α treatment was most likely to be instigated among
those individuals with the highest baseline levels of soluble IL-
2 receptor (sIL-2r), IL-6, and IL-10 (Wichers et al., 2006). It
thus seems that the very same factors that enhance vulnerabil-
ity to stressor-related depression also increase the occurrence of
depressive symptoms in response to IFN-α immunotherapy.
Despite the limited success that has been reported with antide-
pressants in the treatment of depression instigated by life stres-
sors or related factors, SSRIs, such as sertraline, paroxetine, and
citalopram, were reported to be effective in diminishing depres-
sive symptoms otherwise produced by IFN-α (Musselman et al.,
2001a; Hauser et al., 2002; Maddock et al., 2004; Baraldi et al.,
2012). In this regard, paroxetine primarily affected the mood-
related symptoms elicited by IFN-α, but had only modest effects
on fatigue and anorexia (Musselman et al., 2001a; Raison et al.,
2005). These findings are of theoretical significance in linking
IFN-α immunotherapy to depression, but also have practical,
clinical relevance as antidepressants may improve IFN-α tolera-
bility, thus enhancing treatment continuation and effectiveness.
It has to be taken into account that emotional distress associ-
ated with experiencing chronic and/or severe pathological condi-
tions such as hepatitis C, cancer, or stroke may contribute to the
development of depression (Anisman, 2009). As indicated ear-
lier, stressors ordinarily promote cytokine variations in plasma
as well as in brain areas known to be involved in depression
(Steptoe et al., 2007; Audet et al., 2010) and thus, could potentially
influence consequences associated with treatments such as IFN-
α. In fact, immunogenic treatments (e.g., bacterial endotoxin)
applied on a stressor backdropmay synergistically influence these
stress-induced cytokine outcomes, as reported with respect to
monoamines turnover (Gibb et al., 2011). Thus, it is possible that
the enhanced inflammation associated with immune-related con-
ditions or that elicited by IFN-α immunotherapy, when coupled
with the effects associated with the distress of illness, may pro-
mote cytokine and other biological changes (e.g., monoamine
turnover) that exceed those elicited by either condition alone,
thereby increasing the likelihood of depression emerging. In
effect, the consequences of inflammatory changes on depressive
disorders might reflect the conjoint actions of these cytokines and
the stressor backdrop upon which they appear.
POTENTIAL PROCESSES INVOLVED IN PRO-INFLAMMATORY
CYTOKINE PROVOCATION OF DEPRESSION
The specific processes by which activation of the inflammatory
immune system might come to trigger or exacerbate depression
have not been fully identified, although several candidates are
available in this regard. It has been proposed that activation of
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cytokines in the brain (elicited by peripheral inflammation, IFN-
α immunotherapy, tissue damage, or stressors/distress) might
stimulate the enzyme indoleamine 2,3-dioxygenase (IDO), which
is responsible for the degradation of tryptophan within the
kynurenine pathway (O’Connor et al., 2009; Zunszain et al.,
2012). Acceleration of tryptophan catabolism would limit its
availability and thus result in diminished serotonin (5-HT) syn-
thesis, which might favor the development of depressive ill-
nesses (Dantzer et al., 2011; Maes et al., 2011). Alternatively, the
increased rate of tryptophan degradation caused by IDO acti-
vation may enhance the production of N-methyl-D aspartate
(NMDA) receptor antagonists (e.g., kynurenic acid) or ago-
nists (e.g., quinolinic acid) as well as other neurotoxins (e.g.,
3-hydroxykynurenine). These variations within the kynurenine
pathway would then cause the activation of oxidative effects, elicit
mitochondrial dysfunctions, and engender neurotoxic effects
that culminate in depression (Dantzer et al., 2011; Maes et al.,
2011).
It is likely, however, that brain cytokines influence processes
beyond those involving 5-HT or those stemming from neurotoxic
changes subsequent to IDO activation. In this regard, it has been
suggested that stimulation of brain inflammatory processes might
alter neurogenesis and neuroplasticity, known to play an impor-
tant role in depression, through cytokine actions on different
families of growth factors implicated in the growth, differen-
tiation, vascularization, and survival of neurons and synapses
(Duman and Monteggia, 2006; Miller et al., 2009). Specifically,
brain pro-inflammatory cytokines might interact with neu-
rotrophins, including brain-derived neurotrophic factor (BDNF)
and nerve growth factor (NGF), fibroblast growth factors, includ-
ing basic fibroblast growth factor (FGF-2), as well as vascular
endothelial growth factor (VEGF), and erythropoietin (EPO),
and favor the emergence of depressive features (see Anisman
and Hayley, 2012). Alternatively, it is possible that activation of
growth factors (e.g., through the administration of antidepres-
sants, physical exercise, or environmental enrichment) or even
direct administration of growth factors (as an antidepressant
strategy) may come to attenuate depressive symptoms by influ-
encing brain cytokine activity. In the next sections, the impor-
tance of adult neurogenesis and growth factors, especially BDNF,
in relation to depression will be described and the potential inter-
play between pro-inflammatory cytokines and these factors in
promoting depressive illnesses will be discussed.
NEUROGENESIS, GROWTH FACTORS, AND DEPRESSION:
A FOCUS ON BDNF
The generation of new neurons from neural stem cells located
within the subgranular zone of the dentate gyrus of the hip-
pocampus (SGZ) and the subventricular zone of the lateral ven-
tricle (SVZ) and their functional integration to mature neural
networks may occur in the adult brain. This process, adult neu-
rogenesis, has received increasing attention owing to its impor-
tant role in neuronal and synaptic plasticity and in promoting
particular behavioral outcomes. As shown in Table 2, several
growth factors may contribute significantly to adult neuroge-
nesis by promoting the growth, differentiation, maintenance,
and survival of new neurons and synapses (e.g., in the case
of neurotrophins such as BDNF or NGF, or of FGFs), or by
stimulating the growth of new blood vessels required for vascu-
larization of brain tissue (e.g., in the case of VEGF or FGF-2).
Because of their sensitivity to environmental stimuli and their
high degree of plasticity, newborn neurons may contribute to
stress responsiveness and adaptation as well as learning and
memory (Castilla-Ortega et al., 2011). Accordingly, abnormal-
ities in adult neurogenesis as well as impairments of growth
factors functioning, especially in the hippocampus, have been
Table 2 | Subset of growth factors that had been implicated in depressive illnesses: potential roles in behavioral processes and/or
neuropsychiatric disorders.
Growth factor
family
Growth factor
name
Major outcomes Behavioral processes/neuropsychiatric disorderss
Neurotrophins BDNF Growth and differentiation of neurons, survival of existing
neurons and synapses, neuronal and synaptic plasticity
Response and adaptation to stress, learning and
memory, social behaviors.
Depression, anxiety.
NGF Growth and differentiation of neurons, maintenance and
survival of existing neurons, neuronal and synaptic
plasticity
Response to stress, learning and memory.
Depression, anxiety.
Antidepressant effects.
Fibroblast
growth factors
FGF-2 Development of nervous system, differentiation of stem
cells, wound healing, angiogenesis
Response to stress, cognitive processes, social
behaviors.
Depression, schizophrenia.
Antidepressant effects.
Vascular
endothelial
growth factors
VEGF Angiogenesis, vasculogenesis Social behaviors.
Depression, schizophrenia, anxiety.
Antidepressant effects.
EPO Production of blood cells (erythropoiesis), increases
oxygen delivery, wound healing, angiogenesis, neuronal
protection
Cognitive performance.
Antidepressant effects.
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associated with the emergence of neuroaffective and neurocog-
nitive symptoms, including those related to depressive illnesses
(Kempermann and Kronenberg, 2003; Pittenger and Duman,
2008).
IMPAIRMENTS IN ADULT NEUROGENESIS IN RELATION TO
DEPRESSIVE ILLNESSES
Smaller hippocampal volumes, thought to reflect reduced neu-
rogenesis and/or neuron survival, have been reported in patients
with first episode depression as well as in those with recurrent
depression (Sheline et al., 1996; Frodl et al., 2002; MacQueen
et al., 2003; Cole et al., 2011). Post-mortem brain analyses among
non-medicated depressed patients and controls, however, have
not fully succeeded in detecting differences in the number and
proliferation of neural stem cells in the dentate gyrus (Reif et al.,
2006; Boldrini et al., 2009) or disturbances of the cytoarchitec-
ture of the SVZ (Comte et al., 2012). This said, it was observed
that the expression of two neuroplastic markers, doublecortin
and polysialylated-neural cell adhesion molecule, was elevated in
the basolateral amygdala of depressed individuals (Maheu et al.,
2013). This finding is inconsistent with common views concern-
ing the relationship between impairments of neurogenesis and
depression, but as the increased expression of these markers was
apparent in the amygdala, it is possible that this had reflected anx-
iety or elevated stressor reactivity that is frequently comorbidwith
depressive disorders.
A role for adult neurogenesis in depression has come
principally from the observation that antidepressants promoted
neuronal growth and plasticity or attenuated impairments of neu-
rogenesis. In this regard, more neural stem cells and capillaries
were found in post-mortem dentate gyrus of depressed patients
treated with SSRIs compared to non-medicated depressed
patients or healthy controls (Boldrini et al., 2009, 2012), a finding
that was also observed in rats wherein chronic SSRI administra-
tion promoted neuron proliferation in the hippocampus and the
PFC (Malberg et al., 2000; Kodama et al., 2004). Importantly,
among repeatedly stressed non-human primates, enhanced hip-
pocampal neurogenesis during SSRI treatment was necessary
for clinical improvements to occur (Perera et al., 2011). This
said, there have also been reports that antidepressants had no
effects on hippocampal neurogenesis (Cowen et al., 2008), and
even reduced neurogenesis in the SVZ (Ohira and Miyakawa,
2011).
BDNF VARIATIONS IN DEPRESSED PATIENTS
Much of the data supporting a role for impairments of adult
neurogenesis in the emergence of depression has come from the
observation that the neurotrophin BDFN, which plays a funda-
mental role in neurogenesis and neuron survival, was deregulated
in depressed patients or as a result of stressor experiences (e.g.,
depression secondary to stressful events). In line with this per-
spective, reduced serum levels and mRNA expression of BDNF
were reported in drug-free depressed patients compared to those
treated with antidepressants or healthy controls (Karege et al.,
2002; Shimizu et al., 2003; Molendijk et al., 2011; Cattaneo
et al., 2013), and low BDNF levels were negatively correlated
with symptom severity (Shimizu et al., 2003) although it has also
been found that BDNF levels did not parallel core clinical fea-
tures of depression, including severity of symptoms (Molendijk
et al., 2011). Interestingly, reduced hippocampal volume in drug-
free patients suffering from first-episode major depression was
more pronounced among those with lower serum BDNF con-
centrations (Eker et al., 2010). This outcome was also observed
among individuals carrying the BDNF Val66Met polymorphism
(Molendijk et al., 2012), a genetic mutation in which valine (Val)
is replaced by methionine (Met) on one or both alleles of the gene
for BDNF, resulting in diminished secretion of the neurotrophin,
and thus impaired neurogenesis.
Direct evidence of altered BDNF in the human depressed
brain appears to be limited to post-mortem analyses showing
reduced protein density of pro-BDNF in hippocampus (Dunham
et al., 2009), down-regulated mRNA expression of the BDNF
receptor TrkB in the subgenual anterior cingular cortex (Tripp
et al., 2012), and reduced pro- and mature BDNF protein and
mRNA in amygdala (Guilloux et al., 2012). As well, lower BDNF
mRNA expression in post-mortem PFC and hippocampus were
reported individuals that had died through suicide (Dwivedi et al.,
2003).
With respect to the possibility that antidepressants might
stimulate BDNF activity (and thus neurogenesis), post-mortem
analyses indicated that hippocampal concentrations of the neu-
rotrophin were elevated among depressed individuals who had
been treated with antidepressants compared to those who had
not been medicated (Chen et al., 2001). Circulating elevations of
BDNF elicited by antidepressants were also positively correlated
with clinical improvements and in some cases occurred only in
those patients that responded to treatment (Lee and Kim, 2008;
Yoshimura et al., 2009; Cattaneo et al., 2013), supporting the
possibility that attenuation of depressive symptoms elicited by
antidepressants were attributable to BDNF normalization. When
considered together with clinical progress, it was shown that
early plasma BDNF increases (e.g., 7 days after the beginning
of treatment) predicted successful responses to antidepressant
treatment (Dreimüller et al., 2012). These data are, of course,
only correlational and it seems that symptom improvements
following antidepressants might not consistently be accompa-
nied by BDNF normalization. As a matter of fact, although they
were equally effective in improving depressive symptoms, the
SNRI venlafaxine, the SSRI sertraline, and the TCA amitripty-
line increased BDNF levels, whereas neurotrophin concentrations
remained unchanged after treatment with the SSRI escitalopram
and even declined after the SSRI paroxetine (Hellweg et al., 2008;
Matrisciano et al., 2009). Whereas these findings could be fortu-
itous, they might also suggest selectivity regarding the effects of
particular antidepressants on the neurotrophin, or simply indi-
cate that additional processes are involved in the clinical effects of
antidepressants.
STRESSOR EFFECTS ON BDNF: POTENTIAL MODERATING FACTORS
As briefly mentioned earlier, additional support for the possibil-
ity that impairments of neurogenesis may promote depression
has come from a series of reports indicating that stressors elicit
peripheral and central variations of growth factors, especially that
of BDNF. For example, in humans, chronic psychosocial distress
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was negatively correlated with serum levels of BDNF (Mitoma
et al., 2008). Moreover, plasma BDNF reductions elicited by an
acute stressor were prevented by pretreatment with the SSRI
paroxetine (Tamaji et al., 2012). However, despite the consider-
able interest in BDNF as a potential contributor to the evolution
of depression secondary to stressful events, it seems that this rela-
tionship is not always straightforward. In fact, serum increases
of the neurotrophin have also been reported in response to an
acute psychosocial stressor in humans (Meng et al., 2011). It is
likely that the effects of stressors on BDNF in clinical popula-
tions may be influenced by several factors, including the stressor
conditions, previous stressor experiences, and individual differ-
ence factors. In addition, these clinical data have, understandably,
come from studies that evaluated BDNF changes in blood or
from studies among individuals with particular polymorphisms
of the BDNF gene (as will be discussed later). The peripheral
index of BDNF has been related to central concentrations of
the neurotrophin in rats (Angelucci et al., 2011; Klein et al.,
2011), but it was also reported that BDNF in brain was unre-
lated to that evident in plasma (Kyeremanteng et al., 2012).
Even if they were correlated, the plasma BDNF levels might
not be informative with respect to the specific brain regions
that were most responsible for the changes seen peripherally,
a fact that is of particular concern as it has been suggested
that the stressor effects on BDNF may be specific to particular
brain region. This said, the data concerning peripheral BDNF
in relation to stressor effects in humans have been inconsistent,
and what these differences might mean with respect to subse-
quent neurogenesis, neuroplasticity, and depression, remain to be
clarified.
Several animal studies have made it clear that depressive-
like behaviors provoked by acute (e.g., restraint, social defeat)
or chronic (e.g., chronic mild stress, prolonged immobilization)
stressors were accompanied by decreased hippocampal neuro-
genesis (Tanti et al., 2012) as well as down-regulated BDNF
expression in the hippocampus and the PFC (Smith et al., 1995;
Ueyama et al., 1997; Pizarro et al., 2004). Contrary to a BDNF
perspective of stressor-induced depression, however, BDNF ele-
vations in the mPFC, amygdala, and substantia nigra have been
reported after intermittent social defeat (Fanous et al., 2010),
as well as in the neocortex and the nucleus accumbens after a
chronic social stressor (Berton et al., 2006; Schulte-Herbrüggen
et al., 2009). Once again, as in the clinical studies, the direc-
tion of BDNF changes elicited in animals appears to vary across
stressor paradigms and as a function of the specific brain region
examined.
It has been known for some time that different stressors can
call upon diverse neural circuits, and may elicit very different
behavioral outcomes (Anisman andMatheson, 2005). Thus, there
has been some question as to which particular stressors should be
applied in modeling specific psychopathology. A favorite that has
been used in the case of depression is social defeat, as it represents
a naturalistic stressor that engenders profound behavioral impair-
ments as well as marked cytokine, growth factor, and neuro-
chemical variations. In mice, acute social defeat down-regulated
BDNF mRNA expression in the hippocampus, piriform cortex,
and basolateral amygdala (Pizarro et al., 2004). Interestingly,
latency to escape from the aggressor during a social defeat episode
was negatively correlated with BDNF mRNA expression in the
hippocampus (but not in amygdala), suggesting that an active
response strategy during stressor exposure might be associated
with higher hippocampal BDNF (Arendt et al., 2012). Likewise,
when defeat was experienced chronically, depressive-like behav-
iors and hippocampal BDNF protein reductions were apparent
only in those mice that displayed a passive profile during agonis-
tic interactions (Gómez-Lázaro et al., 2011). In line with the view
that elevated BDNF might promote active responding and better
behavioral outcomes, genetic knockdown of BDNF in the ventral
tegmentum enhanced vulnerability to the depressive-like effects
of social defeat (Krishnan et al., 2007), whereas BDNF over-
expression in the hippocampus was associated with resiliency in
response to chronic mild stressor exposure (Taliaz et al., 2011).
Thus, it is possible that intact or enhanced BDNF (existing prior
to stressor exposure or elicited by the stressor), particularly in the
hippocampus, might encourage the use of appropriate defensive
strategies or perhaps more flexibility in adopting these strategies,
thus promoting stressor resilience, and reducing the likelihood
of depression emerging. In the presence of lower BDNF, the
opposite outcomes might occur (e.g., inflexibility in adopting
appropriate response methods), thus favoring stronger adverse
stressor effects and greater vulnerability of developing depressive
features.
It has usually been thought that uncontrollable stressors elicit
more profound biological disturbances than do controllable
stressors. Whereas both types of challenges elicited comparable
reductions of BDNF mRNA expression in the hippocampus, in
the PFC both escapable and inescapable shock increased BDNF
expression, but the BDNF up-regulation was more pronounced
among animals that had been exposed to the controllable stres-
sor (Bland et al., 2007), thus suggesting that the BDNF changes
elicited by shocks in the PFC might be associated with the
degree of control/flexibility animals had over the stressor situa-
tion. Significantly, as well, BDNF elevations that occurred after
psychosocial stressors varied as a function of the dominance
status exhibited during agonistic encounters. Among submis-
sive hamsters, BDNF was up-regulated in the amygdala, whereas
in those hamsters that were dominant, BDNF elevations were
apparent in the hippocampus (Taylor et al., 2011). Similarly,
BDNF expression was elevated in the SVZ and hippocampus
among aged dominant mice but not among their submissive
counterparts (Fiore et al., 2003). Clearly, the BDNF variations
elicited by stressful social interactions might be tied to inter-
individual factors related to dominance or to the methods of
dealing with or responding to stressors that require a certain
control.
Summarizing briefly, the proposition that BDNF is altered
in stress responses and depression has received substantial sup-
port. Indeed, it is even thought that the rapid antidepressant
effects of the NMDA receptor antagonist ketamine might stem
from its stimulating action on BDNF (Liu et al., 2012b). Yet,
there are still data that don’t align nicely with a straightforward
version of the BDNF hypothesis of depression. Either there’s
less to this hypothesis than initially meets the eye, or, more
probably, there are moderating factors that determine whether,
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and under what circumstances, BDNF might be aligned with
depression. It is possible, for instance, that the effects of envi-
ronmental (or experiential) events might be enhanced or made
more cogent in the presence of unaltered or elevated BDNF, and
as a result neuroplasticity would be particularly affected by these
events. As well, experiencing a stressor might elicit a temporary
effect on BDNF (e.g., to help coping with the stressful situa-
tion) that is likely to change with the passage of time and/or with
further stressful experiences. Certainly, the influence of BDNF
is likely to be dictated by the presence of still other endoge-
nous substrates, including other growth and inflammatory factors
and/or, as will be discussed in the next section, particular gene
polymorphisms.
BDNF: GENETIC INFLUENCES ON DEPRESSION
In addition to being influenced by stressors, BDNF might also
play a significant role in how individuals respond to stressors
(behaviorally and physiologically) and might thus also contribute
to whether these responses culminate in depression. In fact, it was
suggested that the impact of stressful-life events on the develop-
ment of growth factor impairments and depressive illnesses might
be modulated by gene polymorphisms that influence neuroplas-
ticity in response to environmental challenges (Belsky and Pluess,
2009). In this regard, child abuse and neglect among individuals
with lifetime depression was associated with lower serum BDNF
levels among carriers of the BDNF Val66Met polymorphism but
not among those homozygous for the Val allele (Elzinga et al.,
2011). Although there have been several comparable reports, it
has also been shown that the presence of the Met allele might
not necessarily lead to BDNF reductions that dispose individu-
als to depressive disorders. As a matter of fact, early adversity did
not affect plasma BDNF levels in carriers of the Met allele nor in
those with a mutation of the 5-HT transporter (5-HTT) in which
a short (s) form of the 5-HTTLPR allele was present. However,
among those individuals homozygous for both the BDNF Val and
the 5-HTTLPR long (l) alleles, marked plasma BDNF reductions
and increased susceptibility to depression were evident in associ-
ation with early life adversity (Buchmann et al., 2012). Similarly,
in adulthood, high depressive scores after chronic stressor experi-
ences were more pronounced among individuals with the BDNF
Val/Val genotype than in those carrying the Met allele (Jiang
et al., 2012). Furthermore, among those homozygous for the 5-
HTTLPR ss alleles, which are a risk factor for later depression
provided that early life or adult stressors are encountered, the
presence of the BDNF Met allele actually had a protective effect
on mental health among those with a history of childhood abuse
(Grabe et al., 2012).
Based on the findings regarding the relationship between low
BDNF and depression, and the role of early and/or adult stressful
events in promoting depressive symptoms, it had been sug-
gested that gene polymorphisms should not be considered as a
“vulnerability factor,” but should instead be viewed as a “plas-
ticity factor” that may favor either positive or negative outcomes
depending upon the individuals specific experiences (Belsky and
Pluess, 2009; Belsky et al., 2009). Thus, as suggested in the case
of 5-HTTLPR (Belsky et al., 2009), elevated BDNF may, “for
better or for worse,” allow for particular experiences to mold
neuronal processes, thereby favoring or buffering against psycho-
logical disturbances in response to further challenges. In effect,
in the presence of the Val/Val alleles, negative experiences or
an impoverished environment would lead to poor psychologi-
cal well-being, whereas nurturing environments would lead to
enhanced psychological well-being and resilience in the face of
later stressors. In the presence of the Met allele, however, reduced
plasticity (related to low BDNF activity) might itself favor the
emergence of depression, but it would also limit the damage that
could otherwise be inflicted by adverse early life experiences. It
could also be argued from this perspective that the positive effects
of a nurturing environment might, unfortunately, also have less
of a positive effect in Met carriers.
EPIGENETIC IMPACT ON BDNF VARIATIONS IN MAJOR DEPRESSION
An obvious question that exists concerns how changes of BDNF
levels and expression come about. From what has been said to
this point, stressors can instill such variations and gene polymor-
phisms may influence whether and to what extent these changes
will occur. However, to account for pathologies such as depres-
sion, PTSD, or addiction, it will be important to identify variables
or processes that result in long-lasting changes of these processes.
In this regard, epigenetic changes associated with adverse early
life experiences as well as those that occur in adulthood have
not only been documented with respect to glucocorticoid recep-
tors (Francis et al., 1999; Weaver et al., 2004; Szyf et al., 2005;
Champagne, 2010) or GABA receptor subunits (Poulter et al.,
2008; Papadopoulos et al., 2011), but also in regard to BDNF.
Specifically, increased DNA methylation of BDNF and altered
prefrontal BDNF expression were reported in adult rats that had
been stressed during the first week after birth, and these epige-
netic BDNF alterations were transmitted to the next generation
of rats (Roth et al., 2009; Roth and Sweatt, 2011). Likewise, strong
stressors administered in adulthood diminished levels and tran-
scriptional activity of BDNF and promoted altered DNA methy-
lation and histone acetylation (Tsankova et al., 2006; Covington
et al., 2009, 2011; Fuchikami et al., 2009, 2010). As expected,
administration of a histone deacetylase (HDAC) inhibitor into
the nucleus accumbens shell (Covington et al., 2009) or the hip-
pocampus (Covington et al., 2011) attenuated the alterations of
histone acetylation as well as depressive-like behaviors elicited
by social defeat. Similarly, reduced hippocampal acetylation of
the acetylcholinesterase gene elicited by a stressor was reversed
by daily administration of an HDAC inhibitor (Sailaja et al.,
2012). The use of HDAC inhibitors in the treatment of depres-
sive illnesses thus seems promising, although the specific relations
between these agents, BDNF variations, and depressive outcomes,
remain to be fully clarified.
CONTRIBUTION OF ADDITIONAL GROWTH FACTORS TO
DEPRESSION: BEYOND BDNF
The case for BDNF involvement in depression has generally been
impressive (Duman and Aghajanian, 2012) but as discussed, the
available data do not fully conform to an accounting based solely
on BDNF-mediated neurogenesis or neuroplasticity. Although
their contribution to depression has not been assessed as exten-
sively as that of BDNF, several reports have pointed to a role for
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additional growth factors in depressive disorders, including FGF-
2, NGF, VEGF, and EPO (see Table 2), as well as macrophage
migration inhibitory factor (MIF), which is considered as a pro-
inflammatory cytokine that has neurogenic actions. These growth
factors, to varying degrees, have been related to depressive dis-
orders, although in the case of VEGF, MIF, and EPO it does
not seem as if they systematically vary in depressed patients.
Nevertheless, it appears that their administration can improve
depressive symptoms, and in some case they might be a nec-
essary condition for the effects of other antidepressants to be
effective.
In the case of FGF-2, down-regulated expression of the pro-
tein and up-regulated expression of its receptor, FGFr1, were
reported in post-mortem frontal cortex and hippocampus of
patients who had been depressed (Evans et al., 2004; Gaughran
et al., 2006). Limited FGF-2 down-regulation was apparent in
those patients that had been treated with antidepressants (Evans
et al., 2004), a finding also seen in mice in which antidepres-
sants increased FGF-2 expression and immunoreactivity in hip-
pocampus and PFC (Gómez-Pinilla et al., 2000; Maragnoli et al.,
2004; Bachis et al., 2008; Elsayed et al., 2012). Furthermore,
blockade of FGF-2 receptor signaling (Elsayed et al., 2012) or
genetic knockout of FGF-2 (Jarosik et al., 2011) antagonized
the behavioral effects of antidepressants in rodent models of
depression, suggesting that this growth factor may be neces-
sary for antidepressant effects to occur. A striking confirmation
of FGF-2 involvement in mediating antidepressant outcomes is
that prefrontal infusion (Elsayed et al., 2012) or intraventricu-
lar microinjections (Turner et al., 2008) of this growth factor
in mice produced antidepressant effects and attenuated impair-
ments of hippocampal neurogenesis elicited by olfactory bulbec-
tomy (Jarosik et al., 2011) or a chronic unpredictable stressor
(Elsayed et al., 2012).
The data regarding NGF involvement in depression have been
more sparse than those involving BDNF and FGF-2. Nonetheless,
reduced NGF levels in plasma were observed among drug-free
depressed patients (Xiong et al., 2011a) and intranasal NGF
administration in rats exerted antidepressant-like effects (Shi
et al., 2010). Interestingly, however, enhanced plasma NGF lev-
els were observed after acute and chronic emotional stressors
in humans (Aloe et al., 1994; Hadjiconstantinou et al., 2001),
thus how NGF variations play out in relation to stressor-elicited
affective states is uncertain.
Unlike BDNF, NGF, and FGF-2, which were reduced in asso-
ciation with depression, plasma levels of VEGF were elevated
(Lee and Kim, 2012) or unchanged (Ventriglia et al., 2009) in
drug-free patients with an acute episode of major depression
and VEGF levels were unrelated to depression scores. In fact,
the only indication of a possible reduction of VEGF levels in
relation to depression comes from reports showing that cere-
brospinal fluid (CSF) VEGF levels were lower in medication-free
suicide attempters compared to healthy controls and that low
CSF VEGF levels were negatively correlated with depression sever-
ity (Isung et al., 2012a), and more pronounced among those
individuals who later completed suicide (Isung et al, 2012b). As
expected, however, concentrations of VEGF increased in remit-
ted depressed patients that had been medicated (Takebayashi
et al., 2010), but these elevations were limited in treatment resis-
tant patients (Carvalho et al., 2012). Yet, it was also reported
that VEGF levels were not altered during SSRI treatment despite
clinical improvements (Ventriglia et al., 2009; Dome et al.,
2012). Although a uniform picture regarding VEGF variations in
depressed patients has yet to emerge, it seems that this growth
factor may be required for an antidepressant effect to be realized,
as several antidepressant treatments up-regulated hippocampal
VEGF expression, and blockade of VEGF inhibited cell prolif-
eration in the SGZ and greatly limited antidepressant outcomes
(Warner-Schmidt and Duman, 2007).
Research concerning MIF in relation to depressive disorders
has similarly led to inconsistent observations. Although circulat-
ing MIF levels and expression were elevated in depressed patients
(Musil et al., 2011; Cattaneo et al., 2013), exogenous admin-
istration of this factor increased BDNF and FGF-2 expression
in vitro and elicited antidepressant effects in vivo (Moon et al.,
2012). Moreover, genetic deletion of MIF blocked the increased
cell proliferation normally elicited by fluoxetine (Conboy et al.,
2011), and limited the antidepressant effects and the increased
hippocampal BDNF expression ordinarily elicited by exercise
(Moon et al., 2012). It thus seems that although the findings
concerning MIF in blood are not congruent with the potential
involvement of this factor in depressive disorders, a better case
exists for central involvement of MIF in depression. Nonetheless,
even if MIF is not involved in the provocation of depressive
symptoms, pharmacologically increasing its levels could still be
a promising therapeutic strategy owing to its actions on other
growth factors or neurotransmitters that influence the course of
the illness.
Like MIF, there is reason to believe that EPO could serve in a
therapeutic capacity in the treatment of depressive disorders. It
is uncertain whether or not EPO in brain tissue is altered among
depressed patients, although it was reported that this factor was
elevated in the CFS (but not in serum) of depressed individ-
uals and that chronic antidepressants reduced CSF EPO levels
(Nakamura et al., 1998). Yet, EPO treatment in rats produced
antidepressant effects (Girgenti et al., 2009) and in clinical tri-
als the administration of EPO alleviated depressive symptoms
(Miskowiak et al., 2012).
Most of the research on the implication of growth factors
in depressive illnesses has concerned BDNF, although increasing
efforts are now being devoted to examine the role of additional
growth factors in depression and/or their contribution to the pos-
itive outcomes of antidepressants. Whereas each growth factor
might exert particular actions, it is likely that a combination of
growth factor variations (rather than impairment of a unique
marker) is involved in the pathogenesis of depressive symptoms
as well as in the clinical outcomes of antidepressant treatments.
Currently, however, the specific contributions of each growth fac-
tor to depression and their potential interactions in the course of
the illness remain to be clarified.
EFFECTS OF PRO-INFLAMMATORY CYTOKINES ON
NEUROGENESIS AND BDNF: RELEVANCE TO DEPRESSION
It will be recalled that increased activity of pro-inflammatory
cytokines and impaired neurogenesis (including reduced BDNF
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functioning) are apparent in drug-free depressed patients and
that clinical improvements resulting from antidepressant treat-
ments have been associated with normalization of particular
cytokines and growth factors. The question remains as to whether
these systems act in parallel or interactively in relation to the
promotion and/or the amelioration of depressive illnesses. It
has been suggested that increased activity of pro-inflammatory
cytokines might alter growth factors, and thus neurogenesis
and plasticity, culminating in depression. It is, indeed, known
that inflammatory responses elicited by immune challenges
and/or stressors may damage microglia and neurons, although
it is still uncertain which mechanisms are responsible for such
outcomes.
Treatment with the bacterial endotoxin LPS not only has
peripheral effects on immune functioning, but also instigates sev-
eral changes within the brain. Of particular significance to the
present discussion is the finding that acute LPS treatment dimin-
ished the number of new neurons generated (Ormerod et al.,
2013), impaired the proliferation of hippocampal precursor cells
(Fujioka and Akema, 2010), and transiently reduced BDNF and
NGF levels in the cortex and hippocampus (Guan and Fang, 2006;
Kranjac et al., 2012). Impairments of hippocampal neurogenesis
induced by LPS were prevented by antidepressants (Peng et al.,
2012) and, importantly, were completely blocked by the non-
steroidal anti-inflammatory agent indomethacin, confirming the
contribution of inflammatory processes to impairments of neu-
rogenesis (Monje et al., 2003). In contrast to acute microglial
activation by LPS, persistently activated microglia did not elicit
disturbances of neurogenesis, probably owing to the limited pro-
inflammatory cytokine elevations in chronically stimulated cells
(Cacci et al., 2008). Thus, it is possible that the degree of microglia
activation resulting from an immunogenic (or stressor) challenge
might be fundamental in determining the extent of disturbed
neurogenesis. In this regard, it has long been considered that
moderate and transient cytokine elevations might be neuropro-
tective, whereas relatively high and persistent levels might be
neurodestructive.
In addition to the non-specific microglia activation elicited
by LPS, administration of particular pro-inflammatory cytokines
may directly affect neurogenesis, and it seems that IL-1β
might be especially potent in this regard. In vitro applica-
tion of IL-1β to neural stem cells reduced their differentiation
(Kuzumaki et al., 2010), decreased their maturation, and pro-
moted proliferation of undifferentiated cells (Zunszain et al.,
2012). Conversely, reduction of IL-1β expression with the toxin,
Cytotoxic Necrotizing Factor 1 promoted neuritogenesis and
synaptogenesis (Malchiodi-Albedi et al., 2012). Likewise, pre-
treatment with the IL-1β antagonist IL-1ra reversed the impaired
neurogenesis elicited by in vitro IL-1β or by stressors (Koo and
Duman, 2008) as well as the down-regulated hippocampal BDNF
and cognitive impairments elicited by social isolation in mice
(Barrientos et al., 2003).
Complicating the view that increased cytokine activity impairs
neurogenesis, it seems that under certain circumstances, acute
administration of pro-inflammatory cytokines may have neu-
roprotective effects. In fact, like IL-1β, in vitro administration
of IL-6 or TNF-α (Monje et al., 2003; Cacci et al., 2005) or
chronic secretion of IL-6 by microglia in adult transgenic mice
(Vallières et al., 2002) reduced hippocampal neurogenesis and
cell survival. However, in vitro application of TNF-α was also
shown to increase proliferation and differentiation of neural
stem cells (Widera et al., 2006; Bernardino et al., 2008), and to
up-regulate exon-IV-bdnf mRNA as well as BDNF protein in pri-
mary astrocytes, probably through its actions on NF-κB (Saha
et al., 2006). Moreover, secretion of IL-6 from LPS-activated
astrocytes promoted proliferation (Wang et al., 2011b), whereas
in adult mice lacking IL-6, proliferation and survival of hip-
pocampal progenitors were compromised (Bowen et al., 2011).
Interestingly, the neuroprotective versus neurotoxic effects of
TNF-α seemed to depend on the receptor subtype activated by
the cytokine, in that stimulation of the TNFR1 receptor inhib-
ited neurogenesis, whereas that of the TNFR2 increased pro-
liferation and survival of neural stem cells (Iosif et al., 2006).
Unlike TNF-α, the differential effects exerted by IL-6 on neu-
rogenesis appeared to vary as a function of the duration of
exposure to the cytokine and other experimental conditions (e.g.,
concentration or amount of IL-6) (Molina-Holgado and Molina-
Holgado, 2010), consistent with the observation that moder-
ate versus high microglia activation might differential influence
neurogenesis, although at present the data regarding the dual
effects of IL-6 are still sparse, thus precluding definitive
conclusions.
In keeping with the view that increased pro-inflammatory
cytokine activity might promote depression through their effects
on growth factors, serum BDNF reductions during the course of
IFN-α treatment were inversely correlated with depressive scores
(Kenis et al., 2011), although it has also been found that depres-
sion severity during IFN-α immunotherapy was associated with
lower BDNF levels prior to treatment, but not with the BDNF
reductions that occurred during treatment (Lotrich et al., 2013).
Moreover, basal serum levels of sIL-2r and of IL-1ra predicted
BDNF reductions during IFN-α therapy, but the two systems were
independently associated with the development of depression
during treatment (Kenis et al., 2011). Cytokine-induced impair-
ments of neurogenesis and growth factors have also been reported
to affect neurochemical processes that had been directly impli-
cated in depression. Application of IL-1β to hippocampal stem
cells blocked their differentiation into serotonergic neurons and
decreased 5-HT concentrations normally released in differenti-
ated cells, an effect that was prevented by IL-1ra (Zhang et al.,
2013). While decreasing neurogenesis of hippocampal progeni-
tors, in vitro application of IL-1β also up-regulated IDO as well
as enzymes involved in the neurotoxic effects associated with
the kynurenine pathway, ultimately limiting tryptophan avail-
ability and promoting neurotoxicity (Zunszain et al., 2012). At
this time there is insufficient information available to firmly
conclude that pro-inflammatory cytokines promote depression
through their actions on BDNF or other growth factors. To be
sure, it does appear that pro-inflammatory cytokines, like stres-
sors, may influence BDNF, and it likewise seems that under
certain conditions BDNF may be related to depression. However,
the linkage between these factors, and the conditions under
which this sequential series of changes occurs, has yet to be fully
defined.
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PRO-INFLAMMATORY CYTOKINE AND BDNF INTERACTIONS
FOLLOWING STROKE: RELEVANCE TO POST-STROKE
DEPRESSION
It would be of considerable interest to evaluate the temporal vari-
ations of pro-inflammatory cytokines and growth factors and
their relationships among depressed patients in the absence of
other comorbid conditions or in animal models of depression.
However, the data concerning the interplay between these factors
has largely come from studies assessing processes that occur fol-
lowing cerebral damage stemming from traumatic brain injury
(TBI) or stroke, especially those variations that occur in the
brain. In this regard, it has been suggested that pro-inflammatory
cytokines released after brain trauma or injury could initially
promote neural generation owing to the growth factor eleva-
tions and/or the neural stem cells that are recruited to the site
of damage in response to the cytokine elevations or, under
specific circumstances, impair neurogenesis and neuroplastic-
ity and compromise clinical and functional recovery (Nakatomi
et al., 2002). The beneficial versus detrimental effects of pro-
inflammatory cytokines on neurogenesis after brain damage are
particularly relevant as a substantial proportion of individuals
that suffer from TBI or stroke will experience depressive symp-
toms during the course of recovery (Whyte and Mulsant, 2002)
and the presence of depression may actually predict poor prog-
nosis for functional recovery and global functioning (Bilge et al.,
2008).
In this regard, elevations of circulating pro-inflammatory
cytokines following central damage in the form of stroke were
associated with later emergence of depression (Yang et al., 2010),
poor prognostic outcomes (Vila et al., 2000;Whiteley et al., 2009),
and predicted mortality at 12 months (Shenhar-Tsarfaty et al.,
2010). In particular, serum IL-18 levels, but not that of IL-6 or
TNF-α, measured 1 and 7 days after stroke were higher in patients
that later developed depression (Yang et al., 2010). Further, serum
IL-1β, IL-1ra, and IL-9 levels measured within 72 h after stroke
predicted fatigue symptoms (Ormstad et al., 2011), but not
depressive symptoms (Ormstad et al., 2012). Beyond the possible
involvement of pro-inflammatory cytokines, lower concentra-
tions of the anti-inflammatory cytokine IL-10 measured shortly
after an ischemic stroke were associated with early neurologi-
cal deterioration (Vila et al., 2003). Likewise, risk of depression
following stroke was enhanced among individuals who carried
alleles associated with reduced anti-inflammatory cytokine func-
tioning (IL-4 and IL-10 gene polymorphisms), although no such
association was found with respect to pro-inflammatory cytokine
polymorphisms (Kim et al., 2012b).
It is interesting that those peripheral cytokines that predict
emergence of depression after a stroke (e.g., IL-18) differ from
the key cytokines typically implicated in depressive illnesses
that occur in other circumstances (e.g., IL-6, TNF-α, or IL-1β).
Nevertheless, a prospective examination of cytokine changes dur-
ing post-stroke recovery revealed that among those patients that
expressed depressive symptoms one year after stroke, serum con-
centrations of IL-6, IL-10, TNF-α, and IFN-γ were concomitantly
increased, supporting the supposition that these key cytokines
might contribute to, or be an index of, post-stroke depressive
symptoms (Su et al., 2012). Although in this study serum IL-1β
levels were too low to be detected (Su et al., 2012), a role for IL-1β
in post-stroke depressive symptoms has been confirmed in ani-
mal models in which the anhedonia elicited by middle cerebral
artery occlusion was attenuated by intracerebrovascular injection
of IL-1ra (Craft and DeVries, 2006).
As in the case of major depression, the mood symptoms that
follow stroke have been related to impairments of BDNF. In this
regard, a meta-analysis indicated that lower serum BDNF lev-
els (measured within a mean of 2 months after stroke) were
associated with the presence of post-stroke depression (Noonan
et al., 2012). Moreover, the 5-HTTLPR ss and the BDNFMet–Met
genotypes, both of which had been implicated inmajor depressive
disorder, were also associated with the presence of depression two
weeks following stroke (Kim et al., 2012a) as well as with poor
prognostic outcomes and worsened physical disability and cog-
nitive functions two weeks and one year after stroke (Kim et al.,
2012c). Paralleling these findings, in animal models, locomotor
deficits and reduced angiogenesis elicited by ischemic stroke were
accentuated in those animals with the Met–Met polymorphism
(Qin et al., 2011).
Although BDNF reductions in stroke patients and animal
stroke models were correlated with functional impairments and
depressive symptoms, very shortly after cerebral ischemia, BDNF
expression in the contralateral and ipsilateral damaged cortex
transiently increased, although in the hippocampus BDNF ele-
vations were delayed (Madinier et al., 2013). This BDNF rise
might have reflected a transient adaptive or compensatory change
as the neurotrophin subsequently declined, especially in corti-
cal areas (Madinier et al., 2013). In fact, shortly after ischemic
stroke, endogenous neural stem cells proliferated, migrated into
the damaged area, and generated new neurons (Nakatomi et al.,
2002). It thus appears that the release of both pro-inflammatory
cytokines and BDNF may be transiently enhanced after stroke,
possibly to protect damaged neuronal tissue (Nakatomi et al.,
2002; Broughton et al., 2012; Madinier et al., 2013). As in the case
of peripheral inflammation elicited by an endotoxin (Cacci et al.,
2008), the neuroprotective versus neurotoxic/neurodegenerative
effects of pro-inflammatory cytokine elevations following brain
damage might depend upon the degree and duration of microglia
activation and the ensuing impact on neurogenesis and related
factors, such as BDNF. Interestingly, in rats, administration of
BDNF shortly after ischemic stroke increased brain levels of the
neurotrophin and prevented neuronal loss and motor deficits
that would have otherwise occurred, an effect that was mediated
by the up-regulated IL-10 and down-regulated TNF-α expres-
sion elicited by the neurotrophin (Jiang et al., 2010, 2011). As
described earlier, it thus seems likely that excessive levels of
cytokines and/or reductions of BDNF, particularly if they persist
for extended periods, as well as the balance between these fac-
tors, might be keyed in determining whether positive or negative
outcomes emerge after stroke.
As alluded to earlier, MIF and EPOmight be related to depres-
sive disorders, although the available data are admittedly limited.
It also seems that these factors may be related to functional
outcomes stemming from stroke or TBI, especially as they are
inducible by hypoxia (Chin et al., 2000; Wang et al., 2009). In
fact, elevated serum and brainMIF during the first days following
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stroke were positively correlated with the severity of brain dam-
age both in patients (Wang et al., 2009) and in a rat stroke
model (Inácio et al., 2011a,b). Moreover, in mice with a genetic
deletion of MIF (Inácio et al., 2011b) or in which MIF was dimin-
ished following housing in an enriched environment (Inácio
et al., 2011c), smaller infarct size and a better functional out-
come were apparent after transient focal ischemia, pointing to a
role for MIF in neuronal death and in functional deficits elicited
by stroke. Unexpectedly, it seems that MIF variations after stroke
might occur independently of changes of other pro-inflammatory
cytokines as genetic deletion ofMIF did not affect ipsilateral IL-1β
up-regulation (in the infarct core and peri-infarct area) or serum
and brain TNF-α elevations that also occur after stroke (Inácio
et al., 2011a,b). Unfortunately, as far as we know, data have not
been reported concerning MIF in relation to post-stroke depres-
sion. As MIF has also been implicated in the up-regulation of
BDNF and FGF-2 in vitro and in the antidepressant effects of dif-
ferent treatments in vivo (Moon et al., 2012), the data regarding
neurotoxic effects of MIF are incongruous and certainly necessi-
tate further investigation. If nothing else, it is necessary to track
the variations of MIF levels over time following stroke and deter-
mine to what extent these might be related to changes of other
cytokines or growth factors and ultimately, to particular depres-
sive and other cognitive outcomes. As indicated earlier, the levels
of cytokines and the damage or beneficial effects that occur, might
vary in a dose-dependent bimodal fashion, and could potentially
vary over time following the brain insult.
In contrast to MIF, EPO has been found to limit neuronal
damage and contribute to functional recovery. In fact, both EPO
and its receptor are expressed in various regions of the brain and
their expression increased during and after ischemia (Sirén et al.,
2001). Furthermore, EPO administration after ischemic stroke or
TBI increased BDNF and VEGF expression and improved func-
tional recovery (Wang et al., 2004; Xiong et al., 2011b). Such
effects were likely not attributable to the hematopoietic effects
of EPO, as treatment with EPO or with its carbamylated form
(C-EPO), which does not influence erythropoiesis (production
of red blood cells), also increased neurogenesis in the dentate
gyrus and limited cell loss as well as spatial learning and senso-
rimotor deficits elicited by TBI (Mahmood et al., 2007; Xiong
et al., 2011b). Interestingly, inhibition of VEGF receptor 2 abol-
ished the neuroprotective effects of EPO after TBI (Xiong et al.,
2011b), supporting a role for this growth factor in the functional
improvements observed.
In addition to its enhancing actions on growth factors (Wang
et al., 2004; Xiong et al., 2011b), it was suggested that increased
EPO expression following brain damage could reduce local pro-
duction of pro-inflammatory markers, possibly limiting further
damage to surrounding tissues and thus preventing subsequent
functional deterioration (Alnaeeli et al., 2012). Up-regulated
serum and brain pro-inflammatory cytokines elicited by TBI
or stroke were attenuated by treatment with rhEPO (Chen
et al., 2007; Bian et al., 2010; Chau et al., 2011), although
EPO administration enhanced BDNF up-regulation elicited by
cerebral ischemia, but did not prevent inflammatory gene up-
regulation (e.g., IL-1β, IL-6, TNF-α) (Mengozzi et al., 2012). As
EPO has been implicated as a promising antidepressant treatment
(Nakamura et al., 1998; Girgenti et al., 2009; Miskowiak et al.,
2012), it appears important to assess its potential effects on
both pro-inflammatory cytokines and growth factors. This said,
several studies have been conducted concerning the safety and
efficacy of EPO administered shortly after stroke. Intravenous
high-dose rhEPO was well-tolerated among patient aged 80 and
over that experienced acute ischemic stroke and was associ-
ated with improved clinical outcomes measured one month later
(Ehrenreich et al., 2002). However, in other studies, EPO had lit-
tle benefit, and in patients with cancer or chronic kidney disease,
thromboembolic complications, and/ormortality risks were asso-
ciated with EPO treatment (Ehrenreich et al., 2009). Thus, there
may be some limitations as to when EPO can be used, and addi-
tional analyses would be necessary to determine other conditions
where its use would be contraindicated.
SUMMARY AND CONCLUSIONS
The perspective that impairments of growth factor functioning,
such as BDNF and others within the different families of growth
factors, might contribute to major depression has gained increas-
ing attention. However, it also seems that these growth factors,
considered individually, might not fully account for the devel-
opment of all of the symptoms comprising depressive illnesses.
In fact, as indicated earlier, inflammatory processes might play
a fundamental role in depression that arise in relation to stress-
ful events, as well as depression that occurs in the course of
chronic inflammatory diseases (e.g., chronic hepatitis C) or of
post-stroke or TBI recovery. It is of particular interest that growth
factors, especially BDNF, and pro-inflammatory cytokines might
have interactive effects on neurogenesis, depending on cytokine
concentrations (and duration of their activation), although it
is uncertain whether they act together or independently in the
provocation or exacerbation of depressive illnesses and/or in
contributing to the clinical outcomes of antidepressants. As
depicted in Figure 1, prenatal and early adverse experiences as
well as the presence of particular gene polymorphisms, includ-
ing that of BDNF, may interact to promote resilience and/or
plasticity in the face of later stressor experiences, or inflamma-
tory immune challenges or diseases. These variations, in turn,
might promote brain changes of corticotropin-releasing hormone
(CRH), monoamines, glutamate, pro-inflammatory cytokines,
and growth factors any of which could contribute to particular
features of depressive illnesses.
The moderate efficacy of SSRIs and SNRIs in the treatment
of depression invigorated the search for the processes associ-
ated with depressive disorders as well as the hunt for biomarkers
that would foretell the occurrence of depression and predict
the efficacy of antidepressant strategies. The perspective that
inflammatory and growth factors might serve in these capaci-
ties has received considerable support, although it appears likely
that some instances of depression might not be related to them
entirely. For example, as indicated earlier, it seems that those
individuals with high inflammatory cytokine levels might be less
responsive to SSRIs and SNRIs. Thus, there is the possibility
that anti-inflammatory agents could be useful as an adjunctive
treatment in attenuating depressive symptoms in these patients,
although their efficacy in this regard has been variable.
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FIGURE 1 | This provides a schematic representation of the potential
interactive influence of prenatal, childhood, and/or adulthood events
and particular genetic variations in affecting inflammatory and growth
factors, ultimately leading to specific depressive illnesses. It is suggested
that particular gene polymorphism, including that of the growth factor BDNF,
may influence vulnerability versus resilience to the emergence of depression,
and that this may be moderated by the presence of adverse childhood
experiences. In this regard, gene polymorphisms are not seen as necessarily
being related to positive or negative outcomes, but instead presence of
adequate factors might permit the environment or particular experiences to
mold subsequent illness vulnerability or resilience. Depending on the
interactions between gene polymorphisms and the presence of early adverse
experiences, subsequent exposure to stressful events or inflammatory
immune challenges (e.g., chronic inflammatory diseases, post-stroke
inflammation) would lead to sensitization of processes that elicit distinctive
variations of brain monoamines, glutamate, growth factors, and/or
pro-inflammatory cytokines and influence how they interact in promoting
specific depressive phenotypes/subtypes.
It seems that medication-free depressed patients may exhibit a
unique profile in which activation of particular pro-inflammatory
cytokines (especially that of IL-6) and reductions of growth
factors (especially that of BDNF) are inversely related to the
severity of depression. Yet, there are troubling findings that
indicate that this supposition is too simplistic. It is possible
that cytokine and/or BDNF contribute to particular symptoms
of depression, or particular depressive subtypes. Despite the
call for an endophenotypic approach to studying mental ill-
nesses, few studies have focused on the link between specific
inflammatory or growth factors and particular characteristics
of depressive disorders. Ultimately, individualized treatment
approaches might be most suitable in dealing with disorders
that involve multiple, but varying symptoms and that seem
biologically heterogeneous. At this time there is ample rea-
son to suggest that particular cytokines (e.g., IL-6) and growth
factors (e.g., BDNF) might serve as biomarkers in predicting
who would be most prone to depression under various chal-
lenge conditions, and which treatment strategies would be most
efficacious.
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